29th Jan 2019 11:21
LONDON (Alliance News) - Shield Therapeutics PLC on Tuesday reported positive results from a long-term study of its lead treatment for iron deficiency, Ferracru.
Shares in the company were trading up 8.5% at 46.00 pence each.
The Feraccru AEGIS-CKD study was a phase III randomized, placebo-controlled, double-blind trial in chronic kidney disease patients with iron deficiency anaemia, which "demonstrated superiority of Feraccru" when the change in haemoglobin after 16 weeks of treatment with Feraccru was compared to placebo.
Furthermore, the improved levels of haemoglobin were retained after 36 weeks.
"Iron deficiency is a significant and progressive issue in patients with chronic renal disease which has been challenging to treat due to poor compliance with traditional oral iron salts," Chief Medical Officer Mark Sampson said.
He added: "These results suggest that Feraccru offers a well-tolerated and effective treatment option which can benefit patients over the long-term."
Related Shares:
Shield Thera